Clinical Trial Update: A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase III trial compares SYS6010 with chemotherapy in patients with recurrent or metastatic breast cancer that is HER2-negative and EGFR-positive; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SYS6010

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Recurrent or Metastatic Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING